Medicine and Dentistry
Patient
100%
Idiopathic Pulmonary Fibrosis
80%
Interstitial Lung Disease
77%
Inpatient
45%
Diagnosis
42%
Therapeutic Procedure
36%
Lung
32%
Diseases
31%
Sarcoidosis
28%
Placebo
25%
Pulmonary Fibrosis
23%
Home Monitoring
18%
Spirometry
18%
Symptom
18%
Forced Vital Capacity
17%
Patient-Reported Outcome
14%
Quality of Life
13%
Assessment
13%
Nintedanib
13%
Coughing
12%
Deterioration
12%
Electronic Nose
12%
Amaurosis
12%
Silo-Filler's Disease
11%
Child
11%
Evaluation Study
10%
Pulmonary Hypertension
10%
Clinical Trial
9%
Consensus
9%
Fatigue
8%
Hypersensitivity Pneumonitis
8%
Forced Expiratory Volume
8%
Mortality
8%
Disease Exacerbation
8%
Auscultation
7%
Infection
7%
Breath Analysis
7%
Pirfenidone
7%
Combination Therapy
7%
Lung Transplantation
6%
Age
6%
Measurement
6%
Drug Therapy
6%
Dyspnea
6%
Hospital
6%
Cough
6%
Survival
6%
Development
5%
Health
5%
Experience
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosing Alveolitis
46%
Interstitial Lung Disease
19%
Sarcoidosis
18%
Nintedanib
17%
Deterioration
12%
Pirfenidone
9%
Diseases
9%
Coughing
8%
Placebo
8%
Blindness
8%
Lung Fibrosis
8%
Adverse Event
6%
Mortality
5%
Side Effect
5%
Nursing and Health Professions
Fibrosing Alveolitis
20%
Patient
19%
Lung Fibrosis
11%
Sarcoidosis
9%
Diseases
8%
Evaluation Study
8%
Diagnosis
7%
Interstitial Lung Disease
7%
Patient-Reported Outcome
7%
Time
6%
Nintedanib
5%
Spirometry
5%